Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 29 March 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Factors associated with discontinuation of anti-TNF inhibitors in IBD 

The most recent issue of Inflammatory Bowel Diseases assessed rates of completion of anti-TNF induction, duration of continued use, intraclass substitution, and dose adjustments.

News image

Antitumor necrosis factor (anti-TNF) medications are known to be highly efficacious in persons with moderate-to-severe inflammatory bowel disease (IBD). 

There is a paucity of data from population-based sources to elucidate persistence with these medications in the general population of IBD. 

Discontinuation of anti-TNF therapy is a marker of lack of effectiveness, intolerance, and patient/physician practice preferences.

Dr Laura Targownik and colleagues identified all persons with IBD in Manitoba who were dispensed infliximab, and adalimumab between 2001 and 2014. 

Subjects were followed longitudinally to assess rates of completion of anti-TNF induction, duration of continued use, intraclass substitution, and dose adjustments. 

11% with IBD were prescribed an anti-TNF drug
Inflammatory Bowel Diseases
Cox proportional hazards models were used to test demographic and clinical factors associated with anti-TNF therapy discontinuation.

Overall, the researchers noted that 11% with IBD were prescribed an anti-TNF drug. 

Approximately four-fifths of persons starting on anti-TNF therapy completed induction. 

At 1 and 5 years, the team noted that persistence rates with the original anti-TNF were approximately 60% and 40%, respectively. 

Immunomodulator use at the time of anti-TNF dispensation was associated with a decreased likelihood of anti-TNF discontinuation in both Crohn's disease and ulcerative colitis. 

The researchers observed that adalimumab users with Crohn's disease who reached maintenance phase had a higher risk of discontinuation than infliximab users.

Dr Targownik's team concludes, "Approximately two-fifths of anti-TNF users discontinue use within 1 year of initiation, and three-fifths will have discontinued at 5 years."

"Concomitant IM therapy has a modest effect on discontinuation rates."

Inflamm Bowel Dis 2017: 23(3): 409-420
17 March 2017

Go to top of page Email this page Email this page to a colleague

 29 March 2017 
Telemedicine in gastroenterology
 29 March 2017 
Red meat and pancreatic cancer risk
 29 March 2017 
Therapeutic goals in Crohn's and rheumatoid arthritis
 28 March 2017 
H. pylori infection in junior high school students
 28 March 2017 
BMI and laporoscopic colorectal surgery
 28 March 2017 
Surgery for gallbladder cancer
 27 March 2017 
H. pylori infection and preeclampsia
 27 March 2017 
Low-cost oral rotavirus vaccine
 27 March 2017 
 Clostridium difficile and colectomy risk in IBD
 24 March 2017 
MRI for local staging of colon cancer
 24 March 2017 
In-office communication about ulcerative colitis
 24 March 2017 
Prevalence of undiagnosed celiac disease
 23 March 2017 
Suspected nonceliac gluten sensitivity
 23 March 2017 
H. pylori and GERD in children
 23 March 2017 
Prespectives on the management of fecal incontinence
 22 March 2017 
Role of microbiota in colorectal surgery
 22 March 2017 
Disease activity in eosinophilic esophagitis
 22 March 2017 
Abdominal visceral fat and new erosive esophagitis
 21 March 2017 
Global trends in colorectal cancer mortality
 21 March 2017 
Pain in pancreatic cancer
 21 March 2017 
Hepatitis C virus–related hepatic myelopathy
 20 March 2017 
NASH treatment and MRI
 20 March 2017 
Metastasis in human colorectal cancer
 20 March 2017 
Fistula treatment of Crohn’s disease
 17 March 2017 
Microbiota in colorectal cancer 
 17 March 2017 
Among Persons with IBD
 17 March 2017 
Acute liver failure in Scotland
 16 March 2017 
Transition readiness scores in adolescents with IBD
 16 March 2017 
Hepatocellular carcinoma risk in different etiologies of cirrhosis
 16 March 2017 
IBD disability index
 15 March 2017 
European consensus on fecal microbiota transplantation 
 15 March 2017 
Hepatocellular carcinoma in the USA 
 15 March 2017 
Hospital readmission for ulcerative colitis
 14 March 2017 
Cardiovascular diseases risk in Barrett's
 14 March 2017 
Assessment of competence in colonoscopy
 14 March 2017 
Cholecystectomy to prevent recurrent pancreatitis
 13 March 2017 
Gallstone disease after colectomy for ulcerative colitis
 13 March 2017 
Achalasia in Chicago since high-resolution manometry
 13 March 2017 
Vedolizumab exposure in pregnancy
 10 March 2017 
Thiopurine therapy in IBD
 10 March 2017 
Complications in advanced fibrosis in Hep C eradication
 10 March 2017 
Intragastric balloons for obesity-related co-morbidities
 09 March 2017 
Intestinal tuberculosis vs Crohn's disease
 09 March 2017 
Predictors of relapse in children with IBD
 09 March 2017 
Direct-acting antiviral regimen for Hep C genotype 3 
 08 March 2017 
Sterile fecal filtrate transfer for C. diff
 08 March 2017 
Drug-induced liver injury
 08 March 2017 
Pharmacotherapy for alcohol dependence
 07 March 2017 
Psychotropic drugs in functional dyspepsia
 07 March 2017 
Vagus nerve and appetite regulation
 07 March 2017 
Gastrointestinal involvement in systemic sclerosis
 06 March 2017 
Small bowel abnormalities in IBS 
 06 March 2017 
Treatment response in NASH with MRI
 06 March 2017 
Intestinal bacterial overgrowth and PPIs in children
 03 March 2017 
Alcohol and risk of gallstone disease
 03 March 2017 
Smoking at colon cancer diagnosis influences survival
 03 March 2017 
Improvements in Crohn’s Disease outcomes over time
 02 March 2017 
Surviving sepsis guidelines
 02 March 2017 
Tenofovir and Hep B transmission in pregnancy
 02 March 2017 
Diagnosis of pediatric IBD 

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us